EP0230298A2 - Stable solid preparation of thiol or thiol ester derivatives - Google Patents
Stable solid preparation of thiol or thiol ester derivatives Download PDFInfo
- Publication number
- EP0230298A2 EP0230298A2 EP87100656A EP87100656A EP0230298A2 EP 0230298 A2 EP0230298 A2 EP 0230298A2 EP 87100656 A EP87100656 A EP 87100656A EP 87100656 A EP87100656 A EP 87100656A EP 0230298 A2 EP0230298 A2 EP 0230298A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- parts
- thiol ester
- ester derivative
- mixed
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007970 thio esters Chemical class 0.000 title claims abstract description 29
- 239000007787 solid Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 125000003396 thiol group Chemical class [H]S* 0.000 title 1
- 239000011734 sodium Substances 0.000 claims abstract description 14
- 239000003792 electrolyte Substances 0.000 claims abstract description 10
- 229920002472 Starch Polymers 0.000 claims abstract description 7
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 7
- 239000008107 starch Substances 0.000 claims abstract description 7
- 235000019698 starch Nutrition 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- -1 butanecarbonyl Chemical group 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 description 30
- 239000000203 mixture Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 23
- 229920002261 Corn starch Polymers 0.000 description 16
- 239000008120 corn starch Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 239000001993 wax Substances 0.000 description 11
- 159000000007 calcium salts Chemical class 0.000 description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 6
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000008379 phenol ethers Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Definitions
- the present invention relates to a stable solid preparation of thiol ester derivative that will be very useful as a drug. More particularly, the present invention pertains to a stable solid thiol ester derivative preparation which contains as active ingredients a thiol ester derivative of the formula [I]: (where R is hydrogen or an acyl group; A is a residue of glycine, sacrosine or a-D-amino acid, the a-carbonyl group of which forms a thiol ester linkage with the sulfur atom; n is an integer 0 or 1; and B is a hydroxyl group or an amino acid residue) or a salt thereof, a water-soluble wax which is solid at ordinary temperatures, and sodium carboxymethyl starch (CMS-Na) and/or a monovalent electrolyte.
- R is hydrogen or an acyl group
- A is a residue of glycine, sacrosine or a-D-amino acid, the a-carbonyl group of which forms
- the present invention relates to a stable solid thiol ester derivative preparation which contains as active ingredients a thiol ester derivative of the formula [I]:
- R is hydrogen, or an acyl group which is selected from the group consisting of an acetyl, butanecarbonyl, cyclopropanecarbonyl, cyclohexanecarbonyl and adamantane- carbonyl groups and which is linked to an a-amino group of an amino acid of A
- A is a residue of glycine, sacrosine or a-D-amino acid, the a-carbonyl group of which forms a thiol ester linkage with the sulfur atom
- n is an integer 0 or 1
- B is a hydroxyl group or an amino acid residue
- a salt thereof a water-soluble wax which is solid at ordinary temperatures, or sodium carboxymethyl starch and/or a monovalent electrolyte.
- Thiol ester derivatives represented by the formula [I] have an action suppressing angiotensin converting enzyme.
- Thiol ester derivatives which are in a solid state are sensitive to moisture. Therefore, when formulated by an ordinary method, they are affected by water contained in an excipient and by adsorption of moisture in the air, causing decomposition or oxidation, and thus resulting in deterioration of their properties. In order to stabilize such unstable thiol ester derivatives, it is necessary to formulate preparations having water in excipients removed as much as possible and to put them in glass bottles or package them in metallic moistureproof materials. Alternatively, in the case of preparations formulated by an ordinary method, they must be protected by, for example, enclosing a desiccant in their packaging. In these practices, the dehumidification required in formulation and rises in the packaging cost both increase the financial burden on the manufacturer, and it is_also troublesome for users to handle and use such preparations.
- the present inventor therefore made various studies in order to obtain a stable solid preparation of thiol ester derivative, and found that a considerably stable solid preparation can be obtained by blending certain additives such as an appropriate wax, a monovalent electrolyte, etc.
- the present invention has been accomplished on the basis of this finding.
- the present invention provides a stable solid thiol ester derivative preparation obtained in such a manner that one or more water-soluble waxes which are solid at ordinary temperatures are added to and mixed with a thiol ester derivative in an amount from 1% to 50%, preferably from 5% to 30%, and this mixture is heated to a temperature above the melting point of the water-soluble wax(es) to allow the wax to become flowable, and is then stirred so that the wax component is coated on and aggregated with the thiol ester derivative.
- the aggregate is cooled to obtain a granulated substance, to which is added sodium carboxymethyl starch and/or a monovalent electrolyte in an amount of 0.01% or more, preferably from 0.1% to 20% with respect to the thiol ester derivative.
- Typical thiol ester derivatives which may be employed in the present invention include N-[3-(N-cyclohexanecarbonyl- 'D-alanylthio)-2-D-methylpropanoyl]-L-proline (hereinafter referred to as "compound 1”), N-[3-(N-pivaloyl-D-alanylthio)-2-D-methylpropano ⁇ l]-L-proline (hereinafter referred to as "compound 2”), D-3-mercapto-2-methylpropanoyl-L-proline (hereinafter referred to as "compound 3”) and N-[3-(N-cyclopropanecarbonyl-D-alanylthio)-2-D-methylpropanoyl]-L-proline (hereinafter referred to as "compound 4"), and also include various salts of these compounds, such as potassium, sodium and lysine salts.
- compound 1 N-[3-(N-cycl
- Water-soluble waxes which are solid at ordinary temperatures and which may be employed in the present invention are any waxes having a melting point of 35°C or higher, preferably from 37°C to 70 0 C. Examples include polyethylene glycols, polyethylene propylene glycols, polyethylene nonyl phenol ethers and polyoxyethylene higher alcohol esters. These waxes may be employed alone or mixed together as desired.
- Heat granulation methods which may be suitably employed in the present invention include generally known granulating methods such as melt granulation, spray granulation, granulation in which a melt is cooled and powdered, fluidized bed granulation and heat granulation by stirring. The feature of these methods resides in that a wax is melted or softened at high temperature, and the ingredients are aggregated by stirring or rolling and then cooled to obtain a granulated substance.
- CMS-Na which is employed in the present invention is generally used as a food additive by the name of carboxymethyl starch.
- Examples of monovalent electrolytes which may be employed in the present invention include sodium chloride, potassium chloride, sodium bromide, lithium chloride and sodium nitrate, and these electrolytes may be mixed together when added to the selected thiol ester derivative.
- Excipients which may appropriately be employed in formulation include lactose, corn starch, potato starch, crystalline cellulose, mannitol, calcium citrate and calcium hydrogenphosphate.
- Solid preparations obtained in accordance with the present invention have excellent stability.
- the calcium salt of the compound 2 was processed in the same way as in Example 1 to obtain tablets.
- the compound 4 was processed in the same way as in Example 1 to obtain tablets.
- Example 1 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 1, and tablets were obtained in the same way as in Example 1.
- a powder mixture obtained in the same way as in Comparative Example 2 was charged into hard capsules by an ordinary method to obtain capsulated preparations.
- Example 5 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 5, and tablets were obtained in the same way as in Example 5.
- Example 6 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 6, and tablets were obtained in the same way as in Example 6.
- Example 7 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and tablets were obtained in the same way as in Example 7.
- Example 11 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 11, and tablets were obtained in the same way as in Example 11.
- Example 12 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 12, and tablets were obtained in the same way as in Example 12.
- Example 13 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 13, and tablets were obtained in the same way as in Example 13.
- Example 7 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then charged into hard capsules by an ordinary method to obtain capsulated preparations.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
- The present invention relates to a stable solid preparation of thiol ester derivative that will be very useful as a drug. More particularly, the present invention pertains to a stable solid thiol ester derivative preparation which contains as active ingredients a thiol ester derivative of the formula [I]:
- Thiol ester derivatives represented by the formula [I] have an action suppressing angiotensin converting enzyme.
- Thiol ester derivatives which are in a solid state are sensitive to moisture. Therefore, when formulated by an ordinary method, they are affected by water contained in an excipient and by adsorption of moisture in the air, causing decomposition or oxidation, and thus resulting in deterioration of their properties. In order to stabilize such unstable thiol ester derivatives, it is necessary to formulate preparations having water in excipients removed as much as possible and to put them in glass bottles or package them in metallic moistureproof materials. Alternatively, in the case of preparations formulated by an ordinary method, they must be protected by, for example, enclosing a desiccant in their packaging. In these practices, the dehumidification required in formulation and rises in the packaging cost both increase the financial burden on the manufacturer, and it is_also troublesome for users to handle and use such preparations.
- The present inventor therefore made various studies in order to obtain a stable solid preparation of thiol ester derivative, and found that a considerably stable solid preparation can be obtained by blending certain additives such as an appropriate wax, a monovalent electrolyte, etc. The present invention has been accomplished on the basis of this finding.
- Thus, the present invention provides a stable solid thiol ester derivative preparation obtained in such a manner that one or more water-soluble waxes which are solid at ordinary temperatures are added to and mixed with a thiol ester derivative in an amount from 1% to 50%, preferably from 5% to 30%, and this mixture is heated to a temperature above the melting point of the water-soluble wax(es) to allow the wax to become flowable, and is then stirred so that the wax component is coated on and aggregated with the thiol ester derivative. Then, the aggregate is cooled to obtain a granulated substance, to which is added sodium carboxymethyl starch and/or a monovalent electrolyte in an amount of 0.01% or more, preferably from 0.1% to 20% with respect to the thiol ester derivative.
- Typical thiol ester derivatives which may be employed in the present invention include N-[3-(N-cyclohexanecarbonyl- 'D-alanylthio)-2-D-methylpropanoyl]-L-proline (hereinafter referred to as "compound 1"), N-[3-(N-pivaloyl-D-alanylthio)-2-D-methylpropanoψl]-L-proline (hereinafter referred to as "compound 2"), D-3-mercapto-2-methylpropanoyl-L-proline (hereinafter referred to as "compound 3") and N-[3-(N-cyclopropanecarbonyl-D-alanylthio)-2-D-methylpropanoyl]-L-proline (hereinafter referred to as "compound 4"), and also include various salts of these compounds, such as potassium, sodium and lysine salts.
- Water-soluble waxes which are solid at ordinary temperatures and which may be employed in the present invention are any waxes having a melting point of 35°C or higher, preferably from 37°C to 700C. Examples include polyethylene glycols, polyethylene propylene glycols, polyethylene nonyl phenol ethers and polyoxyethylene higher alcohol esters. These waxes may be employed alone or mixed together as desired. Heat granulation methods which may be suitably employed in the present invention include generally known granulating methods such as melt granulation, spray granulation, granulation in which a melt is cooled and powdered, fluidized bed granulation and heat granulation by stirring. The feature of these methods resides in that a wax is melted or softened at high temperature, and the ingredients are aggregated by stirring or rolling and then cooled to obtain a granulated substance.
- CMS-Na which is employed in the present invention is generally used as a food additive by the name of carboxymethyl starch.
- Examples of monovalent electrolytes which may be employed in the present invention include sodium chloride, potassium chloride, sodium bromide, lithium chloride and sodium nitrate, and these electrolytes may be mixed together when added to the selected thiol ester derivative.
- Excipients which may appropriately be employed in formulation include lactose, corn starch, potato starch, crystalline cellulose, mannitol, calcium citrate and calcium hydrogenphosphate.
- Solid preparations obtained in accordance with the present invention have excellent stability.
- The following examples are provided for the purpose of further illustrating the present invention but are not to be construed as limiting. It should be noted that "parts" in the following examples denote parts by weight.
- Twenty parts of polyethylene glycol-6000 was added to and mixed with 80 parts of crystalline powder of the calcium salt of compound 1, and the.mixture was then granulated by heating to obtain a granulated substance. Ten parts of CMS-Na was added to and mixed with 90 parts of the obtained granulated substance, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Five parts of CMS-Na was added to and mixed with 95 parts of a granulated substance obtained from the compound 3 in the same way as in Example 1, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Twenty parts of CMS-Na was added to and mixed with 80 parts of a granulated substance obtained in the same way as in Example 1, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Ten parts of C14S-Na was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 1, and the mixture was then charged into hard capsules by an ordinary method to obtain capsulated preparations.
- The calcium salt of the compound 2 was processed in the same way as in Example 1 to obtain tablets.
- The compound 4 was processed in the same way as in Example 1 to obtain tablets.
- Twenty parts of polyethylene glycol-6000 was added to and mixed with 80 parts of crystalline powder of the calcium salt of the compound 1. The mixture was then granulated by heating to obtain a granulated substance. Nine parts of corn starch and one part of sodium chloride were added to and mixed with 90 parts of the obtained granulated substance, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Nine parts of corn starch and one part of potassium chloride were added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Nine parts of corn starch and one part of sodium bromide were added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Nine parts of corn starch and one part of sodium nitrate were added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Twenty parts of polyethylene glycol-6000 was added to and mixed with 80 parts of crystalline powder of the calcium salt of compound 3. The mixture was then granulated by heating to obtain a granulated substance, and 9.9 parts of corn starch and 0.1 part of sodium chloride were added to and mixed with 90 parts of the obtained granulated substance. The mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Twenty parts of polyethylene polypropylene glycol was added to and mixed with 80 parts of crystalline powder of the calcium salt of compound 2, and the mixture was then granulated by heating to obtain a granulated substance. Nine parts of corn starch and one part of sodium chloride were added to and mixed with 90 parts of the obtained granulated substance, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Twenty parts of polyethylene glycol-6000 was added to and mixed with 80 parts of,crystalline powder of the calcium salt of compound 4, and the mixture was then granulated by heating to obtain a granulated substance. Nine parts of microcrystalline cellulose and one part of sodium chloride were added to and mixed with 90 parts of the obtained granu- lated substance, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Nine parts of corn starch and one part of potassium chloride were added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then charged into hard capsules by an ordinary method to obtain capsulated preparations.
- Twenty parts of polyethylene glycol-6000 was added to and mixed with 80 parts of crystalline powder of the calcium salt of compound 1. The mixture was then granulated by heating to obtain a granulated substance, and 9.5 parts of CMS-Na and 0.5 parts of sodium chloride were added to and mixed with 90 parts of the obtained granulated substance. The mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Nineteen parts of mannitol; 0.5 parts of sodium chloride and 0.5 parts of potassium chloride were added to and mixed with 80 parts of a granulated substance obtained in the same way as in Example 15, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 1, and tablets were obtained in the same way as in Example 1.
- Fifty parts of lactose and 30 parts of microcrystalline cellulose were added to and mixed with 20 parts of calcium salt of the compound 1, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- A powder mixture obtained in the same way as in Comparative Example 2 was charged into hard capsules by an ordinary method to obtain capsulated preparations.
- Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 5, and tablets were obtained in the same way as in Example 5.
- Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 6, and tablets were obtained in the same way as in Example 6.
- Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and tablets were obtained in the same way as in Example 7.
- Forty parts of lactose and 20 parts of microcrystalline cellulose were added to and mixed with 40 parts of the calcium salt of compound 1, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
- Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 11, and tablets were obtained in the same way as in Example 11.
- Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 12, and tablets were obtained in the same way as in Example 12.
- Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 13, and tablets were obtained in the same way as in Example 13.
- Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then charged into hard capsules by an ordinary method to obtain capsulated preparations.
- A stability test was carried out on the preparation samples shown in the Examples and Comparative Examples under the following conditions. Six grams of each sample was put in a glass bottle and, with the bottle opened, it was stored in a desiccator at 50oC - 75% RH (relative humidity). After 30 days or 60 days had passed, the residual amount of the principal ingredient in the sample was measured by highspeed liquid chromatography. The results are shown in Tables 1 and 2 below.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT87100656T ATE58833T1 (en) | 1986-01-21 | 1987-01-20 | STABLE SOLID PREPARATION OF THIOL OR THIOLESTER DERIVATIVES. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1070686 | 1986-01-21 | ||
JP10706/86 | 1986-01-21 | ||
JP125901/86 | 1986-06-02 | ||
JP12590186 | 1986-06-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0230298A2 true EP0230298A2 (en) | 1987-07-29 |
EP0230298A3 EP0230298A3 (en) | 1988-01-20 |
EP0230298B1 EP0230298B1 (en) | 1990-12-05 |
Family
ID=26346027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP87100656A Expired - Lifetime EP0230298B1 (en) | 1986-01-21 | 1987-01-20 | Stable solid preparation of thiol or thiol ester derivatives |
Country Status (10)
Country | Link |
---|---|
US (1) | US4783334A (en) |
EP (1) | EP0230298B1 (en) |
KR (1) | KR870007114A (en) |
CA (1) | CA1285487C (en) |
DE (1) | DE3766502D1 (en) |
DK (1) | DK29087A (en) |
ES (1) | ES2018787B3 (en) |
FI (1) | FI84883C (en) |
GR (1) | GR3001175T3 (en) |
NO (1) | NO870233L (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0546358A2 (en) * | 1991-11-20 | 1993-06-16 | Takeda Chemical Industries, Ltd. | Pharmaceutical compositions with angiotensin-II-antagonistic activity |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2355743A1 (en) * | 1972-10-31 | 1975-05-22 | Hoechst Ag | NEW FORMS OF PREPARATION OF N-SQUARE CLAMP TO 2- (5-CHLORO-2-METHOXYBENZAMIDO) -AETHYL SQUARE CLAMP TO -PHENYLSULFONYL-N'-CYCLOHEXYL UREA AND ITS SALT AND MANUFACTURING METHOD FOR THEIR PRODUCTION |
AU507575B2 (en) * | 1975-11-17 | 1980-02-21 | Sandoz Ltd. | Griseofulvin tablet |
US4283407A (en) * | 1977-09-28 | 1981-08-11 | Science Union Et Cie | Thiopropionamides, and the pharmaceutical compositions |
FR2508040A1 (en) * | 1981-06-19 | 1982-12-24 | Chugai Pharmaceutical Co Ltd | PROLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND MEDICAMENT CONTAINING SAME |
EP0072868A1 (en) * | 1981-02-28 | 1983-03-02 | Santen Pharmaceutical Co., Ltd. | Cyclodextrin clathrate compounds of sulfur-containing compounds |
CH656535A5 (en) * | 1986-01-24 | 1986-07-15 | Spirig Ag | Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water |
-
1987
- 1987-01-16 KR KR870000321A patent/KR870007114A/en not_active Application Discontinuation
- 1987-01-16 US US07/004,144 patent/US4783334A/en not_active Expired - Fee Related
- 1987-01-20 NO NO870233A patent/NO870233L/en unknown
- 1987-01-20 CA CA000527701A patent/CA1285487C/en not_active Expired - Fee Related
- 1987-01-20 ES ES87100656T patent/ES2018787B3/en not_active Expired - Lifetime
- 1987-01-20 DE DE8787100656T patent/DE3766502D1/en not_active Expired - Fee Related
- 1987-01-20 DK DK029087A patent/DK29087A/en not_active Application Discontinuation
- 1987-01-20 EP EP87100656A patent/EP0230298B1/en not_active Expired - Lifetime
- 1987-01-21 FI FI870248A patent/FI84883C/en not_active IP Right Cessation
-
1990
- 1990-12-06 GR GR90401026T patent/GR3001175T3/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2355743A1 (en) * | 1972-10-31 | 1975-05-22 | Hoechst Ag | NEW FORMS OF PREPARATION OF N-SQUARE CLAMP TO 2- (5-CHLORO-2-METHOXYBENZAMIDO) -AETHYL SQUARE CLAMP TO -PHENYLSULFONYL-N'-CYCLOHEXYL UREA AND ITS SALT AND MANUFACTURING METHOD FOR THEIR PRODUCTION |
AU507575B2 (en) * | 1975-11-17 | 1980-02-21 | Sandoz Ltd. | Griseofulvin tablet |
US4283407A (en) * | 1977-09-28 | 1981-08-11 | Science Union Et Cie | Thiopropionamides, and the pharmaceutical compositions |
EP0072868A1 (en) * | 1981-02-28 | 1983-03-02 | Santen Pharmaceutical Co., Ltd. | Cyclodextrin clathrate compounds of sulfur-containing compounds |
FR2508040A1 (en) * | 1981-06-19 | 1982-12-24 | Chugai Pharmaceutical Co Ltd | PROLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND MEDICAMENT CONTAINING SAME |
CH656535A5 (en) * | 1986-01-24 | 1986-07-15 | Spirig Ag | Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0546358A2 (en) * | 1991-11-20 | 1993-06-16 | Takeda Chemical Industries, Ltd. | Pharmaceutical compositions with angiotensin-II-antagonistic activity |
EP0546358A3 (en) * | 1991-11-20 | 1994-03-30 | Takeda Chemical Industries Ltd | |
US5534534A (en) * | 1991-11-20 | 1996-07-09 | Takeda Chemical Industries, Ltd. | Pharmaceutical compositions for oral use and method of preparing them |
EP1468683A2 (en) * | 1991-11-20 | 2004-10-20 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for oral use with angiotensin-II-antagonistic activity and method of preparing it |
EP1468683A3 (en) * | 1991-11-20 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition for oral use with angiotensin-II-antagonistic activity and method of preparing it |
Also Published As
Publication number | Publication date |
---|---|
NO870233D0 (en) | 1987-01-20 |
ES2018787B3 (en) | 1991-05-16 |
FI84883C (en) | 1992-02-10 |
FI84883B (en) | 1991-10-31 |
NO870233L (en) | 1987-07-22 |
DE3766502D1 (en) | 1991-01-17 |
DK29087D0 (en) | 1987-01-20 |
GR3001175T3 (en) | 1992-06-30 |
EP0230298B1 (en) | 1990-12-05 |
FI870248A (en) | 1987-07-22 |
KR870007114A (en) | 1987-08-14 |
DK29087A (en) | 1987-07-22 |
US4783334A (en) | 1988-11-08 |
CA1285487C (en) | 1991-07-02 |
EP0230298A3 (en) | 1988-01-20 |
FI870248A0 (en) | 1987-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4065321B2 (en) | Gelatin capsules with controlled water activity | |
EP0361680B1 (en) | Morphine-containing composition | |
US5151433A (en) | Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations | |
US3082154A (en) | Improved free-flowing coated antimalarial salts in particulate form | |
JP4621326B2 (en) | Teprenone stabilized composition | |
DK174893B1 (en) | Clodronate-containing preparations and processes for their preparation | |
AU751575B2 (en) | Pharmaceutical levothyroxine preparation | |
CA2011943A1 (en) | Compositions for the preparation of dosage-form active vitamins d3 and process for preparing stable dosage-form active vitamins d3 by using the same | |
EP0264259B1 (en) | Stabilized pharmaceutical compositions | |
US4666919A (en) | Stabilized pharmaceutical composition containing an isocarbostyril derivative | |
AU3932199A (en) | Pharmaceutical preparation containing levothyroxine sodium | |
EP0394022B1 (en) | Calcium pantothenate composit | |
EP0230298B1 (en) | Stable solid preparation of thiol or thiol ester derivatives | |
KR20060071897A (en) | HIGH PURITY (7α,17α)-17-HYDROXY-7-METHYL-19-NOR-17-PREGN-5(10)-EN-20-YN-3-ONE AND HIGH PURITY COMPOSITION COMPRISING THE SAME | |
EP0063884B1 (en) | Oxazole derivatives, their preparation and use | |
EP0159777A1 (en) | Stabilized 4-carbamoyl-imidazolium-5-olate | |
EP1292598B1 (en) | Process for drying amoxicillin | |
JPS6399012A (en) | Stable solid agent of thiol ester derivative | |
KR100686300B1 (en) | Hydroxypropylmethylcellulose Capsule Preparation Having Teprenone Encapsulated Therein | |
JPH0242811B2 (en) | ||
WO2022075436A1 (en) | A method of producing thyroid hormone-containing formulation | |
JPS59157015A (en) | Muzolimine-containing drug, use and manufacture | |
JPS6056974A (en) | Cyclic dithiodiacetamide, manufacture and drug | |
JP2000219639A (en) | Pharmaceutical composition | |
JPH09268127A (en) | Solid preparation composition containing vitamin b1 derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19880308 |
|
17Q | First examination report despatched |
Effective date: 19890626 |
|
ITTA | It: last paid annual fee | ||
ITF | It: translation for a ep patent filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19901123 Year of fee payment: 5 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE |
|
REF | Corresponds to: |
Ref document number: 58833 Country of ref document: AT Date of ref document: 19901215 Kind code of ref document: T |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19901219 Year of fee payment: 5 Ref country code: GR Payment date: 19901219 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19901227 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19901228 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19910107 Year of fee payment: 5 |
|
REF | Corresponds to: |
Ref document number: 3766502 Country of ref document: DE Date of ref document: 19910117 |
|
ET | Fr: translation filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 19910118 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19910131 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19910311 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19910326 Year of fee payment: 5 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3001175 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19920120 Ref country code: AT Effective date: 19920120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19920121 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19920121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19920131 Ref country code: CH Effective date: 19920131 Ref country code: BE Effective date: 19920131 |
|
BERE | Be: lapsed |
Owner name: CHUGAI SEIYAKU K.K. Effective date: 19920131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19920731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19920801 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PCNP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19920930 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19921001 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: MM2A Free format text: 3001175 |
|
EUG | Se: european patent has lapsed |
Ref document number: 87100656.5 Effective date: 19920806 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 19990201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050120 |